Inactive Instrument

Novoheart Holdings Inc.

NVH

CA67011V1076

Biotechnology & Medical Research

Novoheart Holdings Inc.(TSXV:NVH) added to S&P/TSX Venture Composite Index

April 22, 2019 at 05:00 am

Latest news about Novoheart Holdings Inc.

Novoheart Holdings Inc.(TSXV:NVH) dropped from S&P/TSX Venture Composite Index	23/11/20	CI
Novomed Limited completed the acquisition of 12.6% stake in Novoheart Holdings Inc..	17/11/20	CI
Novomed Limited entered into a definitive arrangement agreement to acquire 12.6% stake in Novoheart Holdings Inc. for CAD 12.6 million.	14/09/20	CI
Novoheart Holdings Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	31/08/20	CI
Novoheart Holdings Inc. Announces Directorship Appointments	19/05/20	CI
Novoheart Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	19/05/20	CI
Novoheart Holdings Inc. Announces Change of its Fiscal Year-End to December 31, from June 30	11/03/20	CI
Novoheart Announces the Completion of a Research and Development Contract Sponsored by a Top 10 Global Pharma	21/01/20	CI
Novoheart Announces an Exclusive Licensing Agreement with Harvard University's Office of Technology Development	16/12/19	CI
Novoheart Announces Change of Fiscal Year-End	30/11/19	CI
Novoheart Holdings Inc. Announces Management Changes	30/11/19	CI
Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca	26/11/19	CI
Novoheart Holdings Inc. Reports Earnings Results for the First Quarter Ended September 30, 2019	18/11/19	CI
Novoheart Holdings Inc. Demonstrates Advanced Capabilities for Drug Screening as Well as Disease Modeling Which Can Lead to Safer Drugs with Better Efficacy, According to New Research	09/09/19	CI
Novoheart Holdings Inc. Reports Earnings Results for the Full Year Ended June 30, 2019	05/09/19	CI
Novoheart Holdings Inc. completed the acquisition of Xellera Therapeutics Limited from Ruby Fame Limited, Marine Bridge International Limited and Ronald Li.	27/06/19	CI
Novoheart Holdings Inc. Announces Executive Changes	17/06/19	CI
Novoheart Holdings Inc. entered into a definitive agreement to acquire Xellera Therapeutics Limited from Ruby Fame Limited, Marine Bridge International Limited and Ronald Li for CAD 32.6 million.	27/05/19	CI
Novoheart Holdings Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2019	17/05/19	CI
Novoheart Holdings Inc.(TSXV:NVH) added to S&P/TSX Venture Composite Index	22/04/19	CI
Novoheart Holdings Inc. Announces Board Appointments	02/03/19	CI
Novoheart Holdings Inc. Reports Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended December 31, 2018	02/03/19	CI
Novoheart Holdings Inc. Announces Executive Changes	07/01/19	CI
Novoheart Holdings Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2018	23/11/18	CI
Novoheart Enters into A Service Agreement with Xellera Therapeutics Limited	31/10/18	CI

Novoheart Holdings Inc is a Canada-based holding company. The Company, through its subsidiary, provides, discovers and develops heart therapeutics. Novoheart's scientific team has pioneered a range of bioengineering technologies collectively known as the MyHeart platform, including first human mini-heart ânovoHeartâ that is capable of fully capable of pumping and ejecting fluid. It is currently partnering with a pharmaceutical company to develop human heart tissues and chambers that carry a hereditary neurodegenerative disease. It is anticipated that the pharmaceutical company will be able to use the developed pathological tissues as a unique drug discovery and drug screening platform for effective therapies targeting the heart-associated issues of this specific disease. Novoheart is currently completing the build out a large commercial laboratory in Asia to enable it to service additional potential commercial partnerships, which are under discussion.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs